Elucid

Elucid is a provider of AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease. From its funding announcement.

$55M Series DRaised 46 days agoBoston, USAHealthcare & MedtechUSA
Visit website →

In their own words

What Elucid says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "provider of AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease". Source

Market expansionProductResearch and developmentCommercial growth

Public signal Read from the company's own description of what the funding supports.

Why now

Where Elucid is today

Elucid announced a Series D round of $55M on 2 September 2026.

Latest round
Series D
Amount
$55M
Announced
2 September 2026
Headquarters
Boston, USA
Sector
Healthcare & Medtech
Growth stage
Series C+
Investors
Not stated
Also participating
Not stated
Relevant leadership
CEO Kelly Huang

Momentum AfterRaise intelligence

AfterRaise Score

73
Building momentum
1 funding signal in the last 90 days
Funding recency
34/40
announced within the last 60 days
Round scale
19/25
round size relative to the market
Funding stage
20/20
Series D
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 2 September 2026
    $55M Series D
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Product launches and new tiers

Opportunities this could create

  • Clinical hiring
  • Provider partnerships
  • Market-entry advisers
  • Local employment infrastructure
  • In-market partnerships

Based on the Healthcare & Medtech sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

High momentum5 connected signals
  • 2 September 2026$55M Series D announced
  • 2 September 2026Stated priority: market expansion
  • 2 September 2026Stated priority: product
  • 2 September 2026Stated priority: research and development
  • 2 September 2026Stated priority: commercial growth

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Elucid is open to

Not yet specified

Elucid has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Elucid

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Elucid?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Healthcare & Medtech companies

See the sector